Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923103 | 0.91 | CNR1 (0.56) | CNR1 | |
| SCHEMBL924670 | 0.90 | — | — | |
| SCHEMBL923041 | 0.89 | CNR1 (0.54) | CNR1 | |
| SCHEMBL923204 | 0.88 | CNR1 (0.52) | CNR1 | |
| SCHEMBL4462400 | 0.84 | CNR2 (0.67) | — | |
| SCHEMBL4566236 | 0.84 | CNR1 (0.53) | CNR1 | |
| SCHEMBL4554921 | 0.82 | CNR1 (0.56) | CNR1 | |
| SCHEMBL922273 | 0.82 | CNR1 (0.66) | CNR1 | |
| SCHEMBL4464876 | 0.82 | CNR2 (0.58) | CNR1 | |
| SCHEMBL924539 | 0.81 | CNR1 (0.58) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875647-B2 | and inverse agonist; 2-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole; obesity and obesity-related metabolic disorders | GREEN CROSS CORPORATION (KR) | 2011-01-25 | — | — | US | disclosed |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | US | disclosed |
| US-20080081815-A1 | Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081815-A1 | Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists | CNR1, CNR2, GPR119 | CNR1 1/4885 |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | CNR2, CNR1, GPR119 | CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.